Compare Campbell Soup Co. (CPB) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs State Street SPDR S&P Biotech ETF — how do they compare? Campbell Soup Co. trades at $22.63 (market cap $6.78B), while State Street SPDR S&P Biotech ETF trades at $159.04. The key difference: Campbell Soup Co. pays a 6.87% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Campbell Soup Co. nearer its low. Which is the better fit depends on your goals.
| CPB | XBI | |
|---|---|---|
Market Cap | $6.78B | — |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $34.03 | $164.28 |
52-Week Low | $20.00 | $86.92 |
Enterprise Value | $13.38B | — |
Dividend Yield | 6.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Campbell's (CPB) trades at $22.56, up 0.6% with bullish technical signals and mixed fundamentals. The stock shows strong valuation metrics with P/E of 11.1 and P/S of 0.7, while recent earnings beat expectations in Q1 2026. Revenue growth remains modest at $10.3B in 2025, though net margins compressed to 5.9%. Technical indicators suggest bullish momentum with support at $22 and resistance at $23.
CPB offers a compelling 7% dividend yield supported by stable cash flows, but faces margin pressure and analyst skepticism with only 3% buy ratings. The company's cost-saving initiatives and new product launches provide potential upside, though competitive pressures and consumer spending trends remain key risks for sustained growth.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
